Rate My Professor Bernd Rehm

Rehm's research centers on microbial biotechnology, biopolymer synthesis, cell factory engineering, and the development of bio-based materials for vaccines, diagnostics, and therapeutics. His team engineers bacterial systems to produce antigen-displaying biopolymer particles for needle-free vaccines targeting malaria, chikungunya, influenza, and Q fever. He has authored or co-authored over 250 scientific publications, with 24,724 citations and an h-index of 73 on Google Scholar. Key works include the books 'Biopolymers for Biomedical and Biotechnological Applications' (2020) and 'Microbial Production of High-Value Products.' Rehm has secured major grants, such as $831,444 from the US National Institutes of Health for a multistage malaria vaccine (2025-2026), $657,964 from the Australian Research Council for nanomedicine delivery (2024-2027), and additional ARC, NHMRC, and Department of Education funding exceeding $3 million. He teaches postgraduate courses like Advanced Molecular Biotechnology and Advanced Protein Engineering and directs the Master of Biotechnology program. Rehm received the Bernard Witholt PHA Award for his contributions to biopolymer research and influences industrial biotechnology and global health vaccine strategies.